NICE u-turn recommends Ipsen’s Cabometyx for kidney cancer
NHS funding for Ipsen’s Cabometyx is now being recommended by the National Institute for Health and Care Excellence to treat kidney cancer.
In a Final Appraisal Determination, the cost watchdog concluded that the drug can be used as a first-line treatment for adults with advanced renal cell carcinoma (RCC).
Cabometyx (cabozantinib) is currently routinely available on the NHS as a treatment for adults with advanced RCC following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Earlier this year, the drug’s scope was expanded in Europe to include treatment-naïve adults with advanced RCC, on the back of data showing patients given Cabometyx had a median progression free survival of 8.6 months versus 5.3 months for those treated initially with sunitinib (Pfizer’s Sutent), marking a 52 percent reduction in the hazard for progression or death.
Read more: http://www.pharmatimes.com/news/nice_u-turn_recommends_ipsens_cabometyx_for_kidney_cancer_1250596
In a Final Appraisal Determination, the cost watchdog concluded that the drug can be used as a first-line treatment for adults with advanced renal cell carcinoma (RCC).
Cabometyx (cabozantinib) is currently routinely available on the NHS as a treatment for adults with advanced RCC following prior vascular endothelial growth factor (VEGF)-targeted therapy.
Earlier this year, the drug’s scope was expanded in Europe to include treatment-naïve adults with advanced RCC, on the back of data showing patients given Cabometyx had a median progression free survival of 8.6 months versus 5.3 months for those treated initially with sunitinib (Pfizer’s Sutent), marking a 52 percent reduction in the hazard for progression or death.
Read more: http://www.pharmatimes.com/news/nice_u-turn_recommends_ipsens_cabometyx_for_kidney_cancer_1250596